Δημοσίευση

A pilot study-is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?

ΤίτλοςA pilot study-is there a role for mitoxantrone pleurodesis in the management of pleural effusion due to lung cancer?
Publication TypeJournal Article
Year of Publication2016
AuthorsSreter, K-B., Jakopovic M., Janevski Z., Samarzija M., Zarogoulidis P., Kioumis I., Mparmpetakis N., Pataka A., Zarogoulidis K., Tsiouda T., Kosmidis C., Mpaka S., Huang H., Hohenforst-Schmidt W., Charalampidis C., Machairiotis N., Zaric B., & Milovancev A.
JournalAnn Transl Med
Volume4
Issue9
Pagination162
Date Published2016 May
ISSN2305-5839
Abstract

BACKGROUND: Lung cancer is the leading cause of malignant pleural effusion (MPE). Management of MPEs remains a clinical challenge due to recurrence and poor quality of life. An ideal sclerosing agent has yet to be found. The aim of this cohort pilot study was to evaluate the role of mitoxantrone pleurodesis (MP) as an alternative to talc sclerotherapy for managing MPEs in lung cancer patients.METHODS: A retrospective chart review was conducted on consecutively admitted patients with MPE to the Department of Post-Intensive Care at the Clinic for Respiratory Diseases "Jordanovac", University Hospital Centre Zagreb, in Croatia.RESULTS: Of 34 patients with MPE, twenty-one (64.8±9.46 years; 47-84 years) with primary lung carcinoma who received MP (30 mg of mitoxantrone) between December 2003 and February 2009 were included in this study. Chest radiographs taken prior to sclerotherapy and at 1-, 2-, and 3-month follow-up were compared. At the post-sclerotherapy evaluation periods, overall success (OS) rates of MP were 88.2% [17.6%, complete response (CR); 70.6%, partial response (PR)], 53.9% (7.7% CR; 46.2% PR), and 45.5% (PR), respectively. Kaplan-Meier median survival from MP until death was 5.2 months, while that from diagnosis of primary lung cancer was 12.3 months.CONCLUSIONS: MP may be a safe and effective method of managing MPE due to lung cancer. Future randomized controlled studies comparing mitoxantrone and talc pleurodesis in lung cancer patients are warranted to elucidate whether a significant difference exists between these agents. Factors affecting success, survival probability, and quality of life also require further investigation.

DOI10.21037/atm.2016.04.15
Alternate JournalAnn Transl Med
PubMed ID27275475
PubMed Central IDPMC4876260

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.